Immunoglobulin M

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024
CD20, Progression-free survival, PFS, Myopathy, Research, Immunoglobulin M, Investment, FDA, Research and development, IGM, FOLFIRI, Myositis, Bevacizumab, Lupus, GAAP, Rheumatoid arthritis, Administration, Patient, Clinical trial, Survival, CD38, SLE, G&A, IND, Colorectal cancer, Pharmaceutical industry

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.
  • Collaboration Revenue: For the fourth quarter and year ended 2023, collaboration revenues were $0.7 million and $2.1 million, respectively, compared to $0.4 million and $1.1 million for the fourth quarter and year ended 2022, respectively.
  • Research and Development (R&D) Expenses: For the fourth quarter and year ended 2023, R&D expenses were $54.2 million and $215.5 million, respectively, compared to $45.0 million and $179.3 million for the fourth quarter and year ended 2022, respectively.
  • General and Administrative (G&A) Expenses: For the fourth quarter and year ended 2023, G&A expenses were $11.6 million and $50.1 million, respectively, compared to $11.6 million and $49.7 million for the fourth quarter and year ended 2022, respectively.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Liver, Bleeding, MCE, USD, SCAP, Immunoglobulin M, FC, Fibrinogen, Wound healing, Standard of care, Fibrin, Risk, Safety, Immunoglobulin G, Element, GRFS, Medicine, Patient, Immunoglobulin A, AFD, Clinical trial, Protein, GRF, Plasma, Factor, CAP, Community-acquired pneumonia, Pharmaceutical industry

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, EST, Conference, IGM, Immunoglobulin M, Webcast

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.
  • A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
  • A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

Retrieved on: 
Monday, January 8, 2024
Sequela, Quality of life, Febrile neutropenia, WM, Death, Anemia, International, IWMF, Disease, Neutropenia, NDA, WAM, News, Cancer, Thrombocytopenia, SCR, Macroglobulinemia, MCI, MRR, Mayo Clinic, Mitt, Patient, Safety, Medicine, Cytopenia, Immunoglobulin M, Pharmaceutical industry

The CLOVER WaM study met its primary endpoint with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p value

Key Points: 
  • The CLOVER WaM study met its primary endpoint with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p value
  • Notably, iopofosine monotherapy achieved an 8% stringent complete remission (sCR) in this highly refractory WM population.
  • “The results from this pivotal study utilizing just four doses of iopofosine monotherapy in heavily pretreated patients are very compelling, demonstrating deep and durable remissions.
  • “Iopofosine’s high major response rate and achievement of the study’s primary endpoint in highly refractory, Waldenstrom’s macroglobulinemia patients exhibits its potentially practice-changing clinical profile.

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
PST, Webcast, Conference, IGM, Immunoglobulin M

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.
  • A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
  • A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Retrieved on: 
Tuesday, December 5, 2023
Workforce, DR5, Sanofi, IND, Antibody, FDA, Colorectal cancer, FOLFIRI, CD20, SLE, IGM, Clinical trial, Rheumatoid arthritis, Inflammation, Investigational New Drug, Lupus, CD38, Bevacizumab, Myopathy, Myositis, Patient, Immunoglobulin M, Vaccine

In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.

Key Points: 
  • In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.
  • As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.
  • “IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • As a part of this strategic refocusing, the Company will halt the following clinical development activities:

IGM Biosciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Myositis, CD38, Safety, Food, Treatment, Progression-free survival, Colorectal cancer, Acute myeloid leukemia, Myopathy, Bevacizumab, IND, Investment, Immunoglobulin G, Clinical trial, Net, Administration, Patient, Research, Lupus, Rheumatoid arthritis, FDA, Autoimmune disease, American College, G&A, Bispecific monoclonal antibody, FOLFIRI, SLE, Immunoglobulin M, GAAP, CD20, R, Antibody, Research and development, IGM, Azacitidine, Pharmaceutical industry, Vaccine, Sanofi

MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.
  • “During the third quarter, we continued to execute across our clinical development pipeline,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • Collaboration Revenue: For the third quarter of 2023, collaboration revenues were $0.5 million, compared to $0.3 million for the same period in 2022.
  • Research and Development (R&D) Expenses: For the third quarter of 2023, R&D expenses were $54.8 million, compared to $48.2 million for the same period in 2022.

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, ASN, PMN, UPCR, Investment, Clinical trial, American Society of Nephrology, APRIL, Glomerular filtration rate, Administration, Patient, TACI, Inflammation, Immunoglobulin A, Neonatal Fc receptor, Lupus, Infection, Research program, BAFF, SLE, ALPN, Immunoglobulin M, MD, Development, EGFR, BCMA, Society, NIH Intramural Research Program, Autoimmunity, Proteinuria, AANEM, Pharmaceutical industry, Sewage treatment, Vaccine, Paint, IgA nephropathy, AbbVie, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Retrieved on: 
Thursday, December 14, 2023
University College London, Community-acquired pneumonia, Ventilation, Intensive care medicine, Immunoglobulin A, Mortality, Inflammation, Multiple organ dysfunction syndrome, Plasma, Septic shock, COVID-19, CAP, Antibody, Patient, Oxygen, Sepsis, SCAP, Immunoglobulin M, Immunoglobulin G, Immune system, Failure, Pneumonia, Vaccine, Pharmaceutical industry

The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).

Key Points: 
  • The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).
  • One major characteristic of sCAP patients is that their immune system becomes dysregulated, which results in inflammation.
  • The results reported, support the currently ongoing investigation of trimodulin in artificial ventilated patients with sCAP with evidence of significant inflammation (ESsCAPE trial).
  • In addition, trimodulin is currently also in development for the treatment of hospitalized, oxygen-supported patients with non-severe CAP, including COVID-19 (TRICOVID trial).

IGM Biosciences to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 7, 2023
EST, Immunoglobulin M, Conference, IGM, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences:

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences:
    Stifel Healthcare Conference on Tuesday, November 14 at 2:25 p.m. EST in New York
    Jefferies London Healthcare Conference on Thursday, November 16 at 9:00 a.m. GMT/ 4:00 a.m. EST in London
    A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
  • A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.